What are your top takeaways from ESMO 2023?  

Breast Cancer Pulled analysis of DESTINY BREAST-01, -02 and -03 trials in patients with brain metastases showing intracranial objective response rate of ~45% in patients who received T-DXd compared to the control arm that had objective response rate of ~12-27%. Updated results of monarchE showed c...

Lung Cancer New first line therapy for advanced EGFR Exon 20 NSCLC patients: The PAPILLION trial [Zhou et al., PMID 37870976] was a Phase 3 clinical trial among patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with documented epidermal growth factor r...

Lung Cancer New standard of care: ALINA - pivotal adjuvant study of alectinib for 2 years vs 4 cycles of adjuvant platinum based doublet chemotherapy for patients with resected ALK-positive stage IB-IIIA NSCLC. Whopping 0.24 HR when it comes to DFS benefits, massive CNS DFS benefits, and while OS i...

GU Cancers The EV-302 trial of Enfortumab Vedotin + Pembrolizumab showed remarkable results, with a median OS of over 31 months, more than 65% of patients having RECIST responses, and durable progression free survival for some patients. The DAD trial was a very interesting Phase I study exploring ...

Breast Cancer The KEYNOTE-756: Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo + Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo  + Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer accrued N=1279 patients with ER+/HER2-, grade 3, T1c-T2/cN1-2 or T...

GU Cancers EV-302 trial. EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC). This trial demonstrated major improvements in o...

GU Cancers EV-302: Establishes EV/Pembro as the new standard of care as frontline treatment for metastatic bladder cancer. CM-901: Nivolumab + Cis/gem first IO/chemo combo to improve OS relative to Cisplatin-based chemotherapy in frontline patients with metastatic disease. Double Antibody Drug Co...

GI Cancers In the PREOPANC-2 study, neoadjuvant chemotherapy with FOLFIRINOX, compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with borderline resectable/resectable PDAC, did not improve OS. Median OS was 21.9 months in the FFX arm and 21.3 months in the CRT arm (HR 0.87,...

GU Cancers EV-302 phase III trial CheckMate 901 phase III trial THOR (cohorts 1 & 2) phase III trial